logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 2 of 2 Items
Showing 1 - 2 of 2 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Conference Material
|
Abstract

Video/Virtually Observed Therapy for patients with drug-resistant tuberculosis in Eswatini: a rapid response to COVID-19 lockdown measures

Aung A, Daka M, Tamrat A, Gwitima T, Chidhuro T,  et al.
2021-05-20 • MSF Scientific Days International 2021: Innovation
2021-05-20 • MSF Scientific Days International 2021: Innovation
WHAT CHALLENGE OR OPPORTUNITY DID YOU TRY TO ADDRESS? WERE EXISTING SOLUTIONS NOT AVAILABLE OR NOT GOOD ENOUGH?
The COVID-19 pandemic has prompted lockdown measures in many places, b...
Journal Article
|
Research

Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini

Vambe D, Kay AW, Furin J, Howard AA, Dlamini T,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Since 2015, Eswatini has been scaling up bedaquiline (BDQ) and delamanid (DLM) based drug-resistant TB treatment regimens under programmatic conditions.

OBJECTIVE: Id...